Orchestrating serendipity
29 August, 2005 by Ann UldridgeAnn Uldridge explains the reasoning behind a new group for women in the biotechnology industry.
NeuroSolutions appoints Sigma Aldrich for scale-up
26 August, 2005 by Helen SchullerNeuroSolutions, the UK based subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has identified and selected Sigma Aldrich to provide scale-up and manufacturing services in relation to its lead pain drug candidate, NSL-043, which is due to enter a phase I clinical trial later this year.
Acrux posts steady revenue growth
25 August, 2005 by Ruth BeranMelbourne-based Acrux (ASX:ACR) posted revenue of AUD$4.8 million for the year ended June 30, 2005, up $1 million from the previous financial year, but also saw an increase in its net loss from $4.2 million in the previous year to $6 million in 2004-05.
Ambri revenue, loss down
25 August, 2005 by Ruth BeranAmbri (ASX:ABI) saw a decrease in its revenue for the 2004-05 financial year of 27 per cent to $1 million (from $1.4 million in the previous year) but the company's loss was also down 22 per cent to $9 million.
Peptech cheered by prostate cancer diagnostic trial
25 August, 2005 by Graeme O'NeillSydney peptide therapeutics company Peptech (ASX:PTD) has reported positive results from a trial of a prostate cancer diagnostic developed by its joint-venture partner Biosceptre International.
Benitec wins IP stoush
25 August, 2005 by Graeme O'NeillGene therapy company Benitec (ASX:BLT) has weathered a head-on challenge from US rival, Nucleonics, to its key DNA-directed RNA-interference (ddRNAi) patents.
In brief: Meditech, Psivida, Regenera, Mesoblast
24 August, 2005 by Staff WritersCancer biopharma Meditech Research (ASX:MTR) has been offered a AUD$2.98 million AusIndustry Commercial Ready Grant over the next three years towards the development and commercialisation of its lead anti-cancer product HyCAMP, which is in Phase II clinical testing.
Former AustCancer CEO to head US biotech
24 August, 2005 by Staff WritersPaul Hopper, who until earlier this year was at the helm of Australian company AustCancer (now Avantogen) has been named the CEO of New York-based clinical stage drug developer Evolve Oncology.
Another flat quarter, but PwC expects biotech recovery
24 August, 2005 by Iain ScottThe latest edition of PricewaterhouseCoopers' quarterly BioForum report is published today, and shows a second consecutive decline in Australian life science stocks in Q4 of the 2004-05 financial year.
Chemeq posts $60.7m loss
24 August, 2005 by Ruth BeranAntimicrobial specialist Chemeq (ASX:CMQ) posted a $60.7 million loss for 2004-04, 509 per cent greater than the $9.9 million it posted in the previous financial year.
Mayne first to offer Medsaic's DotScan as leukaemia test
23 August, 2005 by Ruth BeranMayne Pathology (ASX:MAY) has agreed to provide Sydney-based Medsaic's DotScan test for leukaemia and lymphoma in four states in Australia, with an official launch of the technology at Mayne Health Laverty Pathology in Sydney today.
Pharmaxis to list on Nasdaq
23 August, 2005 by Ruth BeranDrug developer Pharmaxis (ASX:PXS) has received approval to list its American Depositary Receipts (ADRs) on the Nasdaq National Market under the symbol PXSLY.
Sirtex can't explain share surge
23 August, 2005 by Ruth BeranSirtex Medical (ASX:SRX) has been asked by the ASX to explain why its share price soared from $1.90 on August 15 to $2.45 on August 22.
Florigene plans blue rose field trials
23 August, 2005 by Graeme O'NeillMelbourne-based novelty flower developer Florigene is planning the first field trial of its genetically modified roses carrying the company's proprietary 'blue gene' technology.
Pfizer exec: what earlier licensing means for partnering
23 August, 2005 by Ruth BeranBig pharma is licensing new projects earlier, and that means prospective partners need to be creative, a Pfizer licensing director has told a Melbourne meeting.
